Feb 28 |
uniQure GAAP EPS of -$6.47 misses by $0.21, revenue of $15.84M beats by $1.04M
|
Feb 28 |
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
|
Feb 27 |
12 Best Medical Stocks to Buy Under $10
|
Feb 1 |
uniQure: The Valuation Got More Attractive
|
Dec 19 |
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
|
Dec 19 |
Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
|
Dec 19 |
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
|
Dec 12 |
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
|
Dec 10 |
12 Best Genomics Stocks To Buy Now
|
Dec 2 |
Shareholders in uniQure (NASDAQ:QURE) are in the red if they invested three years ago
|